跳转到内容

细胞因子诱导的杀伤细胞

维基百科,自由的百科全书

细胞因子诱导的杀伤细胞Cytokine-induced killer cells, CIK),又称细胞因子激活杀伤细胞,是一组T细胞-自然杀伤细胞NK)样表型的适应免疫细胞混合体。医生通过向外周血单核细胞脐带血单核细胞中注入干扰素-γ抗CD3单克隆抗体、重组人体白细胞介素1族2族等细胞因子诱导形成杀伤细胞。

通常情况下,免疫细胞通过识别呈递在受感染细胞表面的主要组织相容性复合体MHC)而释放细胞因子,引发细胞裂解英语细胞裂解细胞凋亡。然而,CIK细胞具备不受MHC分子限制的杀伤作用,能够识别未能呈递抗原或MHC的受感染细胞甚至恶性肿瘤细胞,并产生迅速及准确的免疫反应。而这些未能呈递MHC的异常细胞不能被T细胞识别及清除[1][2][3]。这一特殊能力,使得终末分化的CD3+CD56+ CIK细胞能够具备抗肿瘤细胞毒性,以对抗MHC限制性和非MHC限制性的癌症细胞的能力。该特征也使得CIK细胞成为治疗癌症病毒感染的潜在治疗方法之一[4]

命名与历史

“细胞因子诱导的杀伤细胞”的命名,来源于终末分化的CIK细胞成熟必须通过细胞因子刺激。一些资料称其为“类似T细胞的自然杀伤细胞”,是因为其与自然杀伤细胞有密切关联。也有人主张将CIK细胞视为自然杀伤细胞的子类[5]

1991年,英戈·G·H·施密特-沃尔夫医生(G.H. Schmidt-Wolf)首次描述CIK细胞[1],并在1999年开始进行癌症临床实验[6]

机制

实验证明淋巴细胞在暴露于干扰素-γ、抗CD3抗体、白细胞介素-1和白细胞介素-2后,能够裂解新鲜的、非培养的癌症细胞(包括原发性和转移性癌细胞)。CIK细胞对这些淋巴因子(特别是白细胞介素-2)敏感,并能够裂解那些对NK细胞或LAK细胞活动产生抗性的肿瘤细胞。

通过抽取外周血或脐带血(比如简单的抽血),医师可以提取出外周血单核细胞脐带血单核细胞。在一定时效期内,提取出来的细胞在体外暴露于干扰素-γ、抗CD3抗体、白细胞介素-1和白细胞介素-2中;这些细胞因子会强烈刺激CIK细胞的增殖和成熟[1][2][4][7]。之后,成熟的CIK细胞将被回输给供体或其他异体。

功能

因为CIK细胞可以杀死自然杀伤细胞或LAK细胞无法裂解的细胞,所以具备独特的功能。

CIK细胞同时具备T细胞NK细胞样表型特征,二者功能的独特组合,产生强有力而又广泛的不受MHC限制的抗肿瘤细胞毒性,具备广谱抗肿瘤效果[2][4]。CIK细胞识别肿瘤的确切机制和其靶向杀伤作用尚不完全清楚。NK样细胞除了通过TCR/CD3英语CD3 (immunology),还通过细胞间接触依赖性的NKG2D英语NKG2DDNAM-1英语DNAM-1NKp30英语NKp30介导来识别肿瘤。这些受体和细胞表面标志使CIK细胞能够消灭不呈递主要组织相容性复合体的细胞,这点可由CIK细胞能够裂解非免疫原性、异基英语allogeneic同系英语syngeneic的肿瘤细胞证明。特别是实体肿瘤细胞和血液肿瘤细胞均呈递NKG2D英语NKG2D配体,CIK细胞能够裂解带有该标记的癌细胞。此外CIK细胞能够特异地识别肿瘤细胞和受病毒感染的细胞,而不对健康细胞做出反应[1][2][3][4]

免疫调节性T细胞会抑制CIK细胞的功能[8]

癌症治疗的临床试验

CIK细胞与白细胞介素-2联合治疗癌症疗法,已经开始在小鼠和人体临床实验中进行,试验显示其毒性较低。

在大量的I期和II期临床试验中,自体和异体CIK细胞对不同肿瘤实体显示出广谱的高毒性潜力,且只有轻微副作用。在许多案例中,CIK细胞治疗完全缓解肿瘤,延长患者生存时间并改善生活质量,甚至在癌症晚期也如此。CIK细胞治疗的使用限制于临床研究,但这种治疗方法也可能在未来进入一线治疗[9][10]

2011年,独立机构国际CIK细胞临床实验目录(International registry on CIK cells,缩写IRCC)成立,该机构致力于收集使用CIK细胞的临床试验数据和后续分析,以描绘CIK细胞研究的最新状况,其主要侧重于评估CIK细胞治疗在临床试验中的效果和副作用。[9][10]

发展及挑战

CIK细胞治疗仍处于临床实验阶段[11][12]。在临床实验中,研究人员通过细胞因子基因技术(例如白细胞介素-2),成功进行了体外细胞转染。CIK细胞经过基因改造,增殖率和细胞毒性显著增加[13]。1999年,基因转染的CIK细胞首次用于已转移的癌症治疗,共有十例患者参加此次实验[6]。开始有证据显示,CIK细胞与树突细胞相互作用,可以进一步提高抗肿瘤疗效;而二者联合培养更可减少调节性T细胞的数量,从而使CD3+CD56+细胞群体扩增[14][15]。在体外研究显示,CIK细胞在对特定肿瘤抗原有特异性的嵌合抗原受体英语chimeric antigen receptor引导下,针对呈递这种抗原的肿瘤细胞的选择和激活能力有所增加[16][17]。体外实验和体内实验还表明,CIK细胞与双特异性抗体英语bispecific antibodies(能同时与细胞毒性效应细胞和致病抗原结合的抗体)联合,活性比单独的CIK细胞要强[18][19]

然而,用于癌症治疗的CIK细胞临床实验很有限[20][21]。最根本的问题在于,以这种方法培养的免疫细胞靶向性不强[22],CIK细胞无法躲过癌症的免疫抑制、预后效果有限[23];与此同时CAR-T(或联合使用[24])在实验中有更好的效果[25]。尽管对于CIK细胞及其治疗方法在学术界存有争议[26],但在中国一些民营医院(莆田系)已经以高昂收费方式进行、部分省份已将未成熟的CIK治疗纳入医保范围,2016年4月爆发的魏则西事件更将CIK细胞及免疫治疗推到风口浪尖[27]

相关条目

参考

  1. ^ 1.0 1.1 1.2 1.3 Schmidt-Wolf, IG; Negrin, RS; Kiem, HP; Blume, KG; Weissman, IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.. The Journal of Experimental Medicine. 1 July 1991, 174 (1): 139–49. PMID 1711560. doi:10.1084/jem.174.1.139. 
  2. ^ 2.0 2.1 2.2 2.3 Schmidt-Wolf, IG; Lefterova, P; Mehta, BA; Fernandez, LP; Huhn, D; Blume, KG; Weissman, IL; Negrin, RS. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.. Experimental hematology. December 1993, 21 (13): 1673–9. PMID 7694868. 
  3. ^ 3.0 3.1 Lu, PH; Negrin, RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.. Journal of immunology (Baltimore, Md. : 1950). 15 August 1994, 153 (4): 1687–96. PMID 7519209. 
  4. ^ 4.0 4.1 4.2 4.3 Pievani, A; Borleri, G; Pende, D; Moretta, L; Rambaldi, A; Golay, J; Introna, M. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity.. Blood. 22 September 2011, 118 (12): 3301–10. PMID 21821703. doi:10.1182/blood-2011-02-336321. 
  5. ^ Godfrey, DI; MacDonald, HR; Kronenberg, M; Smyth, MJ; Van Kaer, L. NKT cells: what's in a name?. Nature reviews. Immunology. March 2004, 4 (3): 231–7. PMID 15039760. doi:10.1038/nri1309. 
  6. ^ 6.0 6.1 Schmidt-Wolf, IG; Finke, S; Trojaneck, B; Denkena, A; Lefterova, P; Schwella, N; Heuft, HG; Prange, G; Korte, M; Takeya, M; Dorbic, T; Neubauer, A; Wittig, B; Huhn, D. Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma.. British Journal of Cancer. November 1999, 81 (6): 1009–16. PMID 10576658. doi:10.1038/sj.bjc.6690800. 
  7. ^ Introna, M; Pievani, A; Borleri, G; Capelli, C; Algarotti, A; Micò, C; Grassi, A; Oldani, E; Golay, J; Rambaldi, A. Feasibility and safety of adoptive immunotherapy with CIK cells after cord blood transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. November 2010, 16 (11): 1603–7. PMID 20685246. doi:10.1016/j.bbmt.2010.05.015. 
  8. ^ Li, H; Yu, JP; Cao, S; Wei, F; Zhang, P; An, XM; Huang, ZT; Ren, XB. CD4 +CD25 + regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients.. Journal of clinical immunology. May 2007, 27 (3): 317–26. PMID 17468835. doi:10.1007/s10875-007-9076-0. 
  9. ^ 9.0 9.1 Schmeel, LC; Schmeel, FC; Coch, C; Schmidt-Wolf, IG. Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the international registry on CIK cells (IRCC).. Journal of cancer research and clinical oncology. 8 November 2014, 141: 839–49. PMID 25381063. doi:10.1007/s00432-014-1864-3. 
  10. ^ 10.0 10.1 Hontscha, C; Borck, Y; Zhou, H; Messmer, D; Schmidt-Wolf, IG. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC).. Journal of cancer research and clinical oncology. February 2011, 137 (2): 305–10. PMID 20407789. doi:10.1007/s00432-010-0887-7. 
  11. ^ No proof for alleged health benefits of DC-CIK. South China Morning Post Publishers Ltd. 2012-10-23 [2016-05-02]. (原始内容存档于2016-04-26) (英语). 
  12. ^ Linn Yeh-Ching; Yong Hao-Xiang; Niam M; Lim TJ; Chu S; Choong A; Chuah C; Goh YT; Hwang W; Loh Y; Ng HJ; Suck G; Chan M; Koh M. A phase I/II clinical trial of autologous cytokine-induced killer cells as adjuvant immunotherapy for acute and chronic myeloid leukemia in clinical remission. Cytotherapy. 2012-08, 14 (7): 851–859. doi:10.3109/14653249.2012.694419 (英语). 
  13. ^ Jäkel, Clara E; Schmidt-Wolf, Ingo GH. An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells. Expert Opinion on Biological Therapy. July 2014, 14 (7): 905–916. doi:10.1517/14712598.2014.900537. 
  14. ^ Märten, A; Ziske, C; Schöttker, B; Renoth, S; Weineck, S; Buttgereit, P; Schakowski, F; von Rücker, A; Sauerbruch, T; Schmidt-Wolf, IG. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations.. Journal of immunotherapy (Hagerstown, Md. : 1997). 2000, 24 (6): 502–10. PMID 11759073. doi:10.1097/00002371-200111000-00007. 
  15. ^ Schmidt, J; Eisold, S; Büchler, MW; Märten, A. Dendritic cells reduce number and function of CD4+CD25+ cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma.. Cancer immunology, immunotherapy : CII. November 2004, 53 (11): 1018–26. PMID 15185013. doi:10.1007/s00262-004-0554-4. 
  16. ^ Hombach, AA; Rappl, G; Abken, H. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".. Molecular therapy : the journal of the American Society of Gene Therapy. December 2013, 21 (12): 2268–77. PMID 23985696. doi:10.1038/mt.2013.192. 
  17. ^ Tettamanti, Sarah; Marin, Virna; Pizzitola, Irene; Magnani, Chiara F.; Giordano Attianese, Greta M. P.; Cribioli, Elisabetta; Maltese, Francesca; Galimberti, Stefania; Lopez, Angel F.; Biondi, Andrea; Bonnet, Dominique; Biagi, Ettore. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. British Journal of Haematology. May 2013, 161 (3): 389–401. doi:10.1111/bjh.12282. 
  18. ^ Chan, JK; Hamilton, CA; Cheung, MK; Karimi, M; Baker, J; Gall, JM; Schulz, S; Thorne, SH; Teng, NN; Contag, CH; Lum, LG; Negrin, RS. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study.. Clinical cancer research : an official journal of the American Association for Cancer Research. 15 March 2006, 12 (6): 1859–67. PMID 16551871. doi:10.1158/1078-0432.ccr-05-2019. 
  19. ^ Tita-Nwa, F; Moldenhauer, G; Herbst, M; Kleist, C; Ho, AD; Kornacker, M. Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells.. Cancer immunology, immunotherapy : CII. December 2007, 56 (12): 1911–20. PMID 17487487. doi:10.1007/s00262-007-0333-0. 
  20. ^ 肿瘤免疫疗法“中外有别” 行业标准亟待完善. 搜狐网. 2015-07-09 [2016-05-02]. (原始内容存档于2016-05-02). 
  21. ^ Stuart H. Orkin, David E. Fisher, A. Thomas Look, Samuel Lux IV, David Ginsburg, David G. Nathan Elsevier Health Sciences. Oncology of Infancy and Childhood , 编. Oncology of infancy and childhood. Philadelphia: Saunders Elsevier. 2009: 228. ISBN 9781437721386. 
  22. ^ Zhong R; Teng J, Han B, Zhong H. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer.. Cancer Immunol Immunother. 2011-10, 60 (10): 1497–1502 [2016-05-02]. doi:10.1007/s00262-011-1060-0. (原始内容存档于2016-09-20) (英语). 
  23. ^ Shi SB1; Ma TH, Li CH, Tang XY. Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer.. Tumori. 2012-05-06, 98 (3): 314–319. doi:10.1700/1125.12398 (英语). 
  24. ^ Hombach, Andreas A.; Rappl, Gunter; Abken, Hinrich; Gunter Rappl, Hinrich Abken. Arming cytokine induced killer cells with chimeric antigen receptors (CARs): CD28 outperforms combined CD28-OX40 "super-stimulation". Molecular Therapy. 2013-08-28 [2016-05-04]. doi:10.1038/mt.2013.192. (原始内容存档于2014-07-19). 
  25. ^ 魏则西治疗的疑团 监管缺位背后的疗法之争. 新京报. 2016年5月4日 [2016-05-04]. (原始内容存档于2016-05-06). 
  26. ^ 王文浩; 李贵新, 刘锦. CIK 细胞在肿瘤过继细胞治疗中的疗效评价 (PDF). 国际肿瘤学杂志. 2013, (40.002): 106–108 [2016-05-04]. (原始内容存档 (PDF)于2016-08-04). 
  27. ^ 罗朝淑. 滥用之殇:肿瘤免疫治疗救不了魏则西. 科技日报. [2016-05-04]. (原始内容存档于2016-06-02). 

外部链接